WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has approved Katerzia (amlodipine) Oral Suspension, 1 mg/mL, the first and only FDA-approved amlodipine oral suspension. Katerzia is indicated […]
WOBURN, Mass. (Mar. 26, 2019) – CutisPharma, Inc. announced today the opening of its new corporate headquarters in Woburn, Mass. along with an expansion of its manufacturing operations at its existing location in Wilmington, Mass. The announcement was made at a grand opening ceremony held on Tuesday, March 26, 2019, and attended by the Honorable […]
WILMINGTON, Mass. (Mar. 25, 2019) – CutisPharma, Inc. announced today the commercial availability of FIRST-Atenolol grape-flavored oral solution compounding kit. FIRST-Atenolol provides pharmacists with a convenient, high-quality, standardized way to compound an oral liquid Atenolol solution for patients who are not otherwise served by commercially available therapies, such as those who are unable to swallow […]
CutisPharma is a strong believer in giving back to the community. Each year we encourage our employees to take a step away from the office, and take part in events that lend a helping hand to those in need. This year we were lucky enough to have our employees, over the course of two days, […]
CutisPharma was a proud sponsor of the ASHP Midyear 2018 and featured a 20’ X 40’ booth representing both our FI℞ST® Kit family portfolio of prescription unit-of-use compounding kits and our FDA-approved vancomycin hydrochloride for oral solution (FIRVANQ™).
ASHP’s Midyear Clinical Meeting and Exhibition is the largest gathering of pharmacy professionals in the world. Attended by […]
We are pleased to be attending and participating in the 6th Annual C.Diff conference and Health Expo for the second year. Our team stands with the C Diff Foundation and continues to support its education and advocacy efforts in benefiting patients impacted by Clostridium difficile Infection.
The nonprofit C Diff Foundation is dedicated to supporting global […]
This year, CutisPharma proudly attended the Fight C. Diff gala for a second year! Our team supported the foundation in raising awareness for C.Diff infection. The Peggy Lillis Foundation is building a nationwide CDI awareness movement by educating the public, empowering advocates and shaping policy.
Since 2000, CDIs have gone from being a “nuisance” disease to […]
CutisPharma was a proud sponsor of IDWeek 2018 for the second year! This is an inclusive meeting that offers access to internationally recognized leaders in the field and the opportunity to network with the most highly respected health professionals in infectious diseases, including HIV. This was a great place for our team to showcase our […]
This year, we were proud sponsors of SIDP Annual Meeting 2019! The Society of Infectious Diseases Pharmacists (SIDP) is an association of pharmacists and allied healthcare professionals dedicated to promoting the appropriate use of antimicrobial agents. Among those in attendance at SIDP Annual were individuals engaged in patient care, research, teaching, pharmaceutical industry and government. […]
Unrestricted Grant from Company to Support Awareness and Advocacy Efforts
WILMINGTON, Mass. (November 1, 2017) – – CutisPharma and the C Diff Foundation announced the launch of a
partnership today, the first day of Clostridium difficile awareness month. As part of the partnership, CutisPharma will award an unrestricted grant to the Foundation to further support its […]
An editorial in this week’s issue highlights the enhancement in compounding regulations over the last few years and the valuable role that FIRST Compounding Kits play to help facilitate compliance with the updated regulations governing compounding.
Robert M. Palladino named as Chief Financial Officer, Dr. Yatindra Joshi as Special Advisor to the Board of Directors to accelerate Strategic Growth Plan activities.
WILMINGTON, Mass. (August 1, 2017) – CutisPharma today announced the appointments of Robert M. Palladino as Chief Financial Officer and Yatindra Joshi, Ph.D., as a Special Advisor to the Board of […]
The California Board of Pharmacy’s Enforcement and Compounding Committee recently recommended a revision to state regulations that compounding kits not be included within their definition of compounding. The proposed revision by the California Board of Pharmacy would be a significant validation of the value of FIRST kits in helping facilitate compliance with all applicable compounding […]
An evaluation by Bunnell et.al. highlighted the potential adverse consequences of cost-related non-adherence to oral vancomycin therapy and the challenges that clinicians face when prescribe oral vancomycin capsules.
New proposed regulations under 247 CMR Board of Registration in Pharmacy suggest that pharmacists using FIRST Compounding kits would be exempt from certain requirements for pharmacists to independently verify the quality and purity of compounded formulations. The proposed language validates the value of FIRST kits in helping facilitate compliance with all applicable compounding regulations and […]
Metronidazole and Baclofen Kits Enable Safe, Easy and Compliant Preparation by Pharmacists
WILMINGTON, Mass. (October 3, 2016) – CutisPharma, a specialty pharmaceutical company that develops and distributes kits used by pharmacists to safely create compounded medications, has expanded its product portfolio to include FI℞ST® Unit-of-Use Prescription Compounding Kits for Metronidazole and Baclofen oral suspensions, two medications […]